CLINICAL GUIDELINES

Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia

CLINICAL GUIDELINES ,

GROUP OF AUTHORS UNDER THE SUPERVISION OF ACADEMICIAN VG SAVCHENKO

AG Turkina1, AYu Zaritskii2, VA Shuvaev3, EYu Chelysheva1, EG Lomaia2, EV Morozova4, AK Golenkov5, TI Pospelova6, OA Shukhov1, MS Fominykh3, GA Gusarova1, LA Kuz’mina1, AO Abdullaev1, IS Martynkevich3

1 Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

2 Federal Almazov North-West Medical Research Centre, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341

3 Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

4 RM Gorbacheva Scientific Research Institute of Pediatric Hematology and Transplantation; Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022

5 NF Vladimirskii Moscow Regional Research Clinical Institute, 61/2 Shchepkina str., Moscow, Russian Federation, 129110

6 Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation, 630091

For correspondence: Anna Grigor’evna Turkina, DSci, Professor, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; e-mail: turkianna@yandex.ru

For citation: Turkina AG, Zaritskii AYu, Shuvaev VA, et al. Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia. Clinical oncohematology. 2017;10(3):294–316 (In Russ).

DOI: 10.21320/2500-2139-2017-10-3-294-316

ABSTRACT

This article is the 4th edition of the recommendations for the diagnosis and treatment of chronic myeloid leukemia. The group of authors reviewed and discussed relevant new publications, and included the significant remarks and comments of experts. Particular attention was paid to the control of risk factors for the development of arterial vascular events and their prevention, and adverse effects of the long-term therapy with tyrosine kinase inhibitors, which were being increasingly reported in recent years.

Keywords: chronic myeloid leukemia, tyrosine kinase inhibitors, molecular response, vascular complications, therapy algorithm.

Received: November 15, 2016

Accepted: February 19, 2017

Read in PDF (RUS)pdficon

REFERENCES

  1. Куликов С.М., Виноградова О.Ю., Челышева Е.Ю. и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009–2012 гг. Терапевтический архив. 2014;86(7):24–30.
    [Kulikov SM, Vinogradova OYu, Chelysheva EYu, et al. Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009–2012 population-based study. Terapevticheskii arkhiv. 2014;86(7):24–30. (In Russ)]
  2. Туркина А.Г., Голенков А.К., Напсо Л.И. и др. Российский регистр по лечению хронического миелоидного лейкоза в рутинной клинической практике: итоги многолетней работы. Эффективная фармакотерапия. 2015;10:8–13.
    [Turkina AG, Golenkov AK, Napso LI, et al. Chronic Myeloid Leukemia Russian Register in Routine Clinical Practice: Results of the Multi-Year Work. Effectivnaya farmakoterapiya. 2015;10:8–13. (In Russ)]
  3. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343–56.
  4. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003;138(10):819–30. doi: 10.7326/0003-4819-138-10-200305200-00010.
  5. Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114(22):462.
  6. Зарицкий А.Ю., Ломаиа Е.Г., Виноградова О.Ю. и др. Факторы прогноза при терапии иматиниба мезилатом у больных в хронической фазе Рh-позитивного хронического миелолейкоза: данные многоцентрового нерандомизированного исследования в России. Терапевтический архив. 2007;79(8):17–22.
    [Zaritskii AYu, Lomaia EG, Vinogradova OYu, et al. Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomyzed trial in Russia. Terapevticheskii arkhiv. 2007;79(8):17–22. (In Russ)]
  7. Голенков А.К., Высоцкая Л.Л., Трифонова Е.В. Эффективность программы лечения хронического миелолейкоза гливеком в широкой клинической практике. Альманах клинической медицины. 2008;18:9–13.
    [Golenkov AK, Vysotskaya LL, Trifonova EV. Efficacy of chronic myeloid leukemia treatment with glivec in the wide spread clinical practice. Almanakh klinicheskoy meditsiny. 2008;18:9–13. (In Russ)]
  8. Челышева Е.Ю., Галактионова А.В., Туркина А.Г. Проблемы приверженности терапии хронического миелолейкоза: понять пациента и найти решения. Клиническая онкогематология. 2013;6(2):157–65.
    [Chelysheva EYu, Galaktionova AV, Turkina AG. The problem of adherence to therapy in chronic myeloid leukemia: understanding the patient and making a decision. Klinicheskaya onkogematologiya. 2013;6(2):157–65. (In Russ)]
  9. Абдулкадыров К.М., Ломаиа Е.Г., Шуваев В.А. и др. Оценка выживаемости, достижения молекулярного, цитогенетического ответов у пациентов с хроническим миелолейкозом в хронической фазе, получающих терапию иматинибом: данные девятилетнего популяционного наблюдения больных хроническим миелолейкозом Санкт-Петербурга. Вестник гематологии. 2010;5(2):5.
    [Abdulkadyrov KM, Lomaia EG, Shuvaev VA, et al. The analysis of survival and molecular and genetic response rate in patients with chronic myeloid leukemia in chronic phase receiving imatinib: the data from 9-year population study of patients with chronic myeloid leukemia in Saint Petersburg.) Vestnik gematologii. 2010;5(2):5. (In Russ)]
  10. Шухов О.А., Туркина А.Г., Челышева Е.Ю. и др. Отдаленные результаты терапии ингибиторами тирозинкиназ у больных хроническим миелолейкозом в ранней и поздней хронической фазе. Клиническая онкогематология. 2016;9(3):368.
    [Shukhov OA, Turkina AG, Chelysheva EYu. Long-term results of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients in early and late chronic phase. Clinical oncohematology. 2016;9(3):368. (In Russ)]
  11. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. и др. Хронический миелолейкоз: многолетний опыт таргетной терапии. Клиническая онкогематология. 2016;9(1):54–60. doi: 10.21320/2500-2139-2016-9-1-54-60.
    [Abdulkadyrov KM, Shuvaev VA, Martynkevich IS, et al. Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy. Clinical oncohematology. 2016;9(1):54–60. doi: 10.21320/2500-2139-2016-9-1-54-60. (In Russ)]
  12. Лазорко Н.С., Ломаиа Е.Г., Романова Е.Г. и др. Ингибиторы тирозинкиназ второго поколения и их токсичность у больных в хронической фазе хронического миелолейкоза. Клиническая онкогематология. 2015;8(3):302–8. doi: 10.21320/2500-2139-2015-8-3-302-308.
    [Lazorko NS, Lomaia EG, Romanova EG, et al. Second Generation Tyrosine Kinase Inhibitors and Their Toxicity in Treatment of Patients in Chronic Phase of Chronic Myeloid Leukemia. Clinical oncohematology. 2015;8(3):302–8. doi: 10.21320/2500-2139-2015-8-3-302-308. (In Russ)]
  13. Шуваев В.А., Фоминых М.С., Мартынкевич И.С. и др. Коррекция нейтропении и тромбоцитопении, обусловленных терапией ингибиторами тирозинкиназ при хроническом миелолейкозе. Онкогематология. 2013;4:7–12.
    [Shuvaev VA, Fominykh MS, Martynkevich IS, et al. Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients. Onkogematologiya. 2013;4:7–12. (In Russ)]
  14. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START a trial. J Clin Oncol. 2009;27(21): 3472–9. doi: 10.1200/Jco.2007.14.3339.
  15. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias. N Engl J Med. 2006;354(24):2531–41. doi: 10.1056/NEJMoa055229.
  16. Cortes J, Rousselot P, Kim D, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8): 3207–13. doi: 10.1182/blood-2006-09-046888.
  17. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–51. doi: 10.1056/NEJMoa055104.
  18. Kantarjian H, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540–6. doi: 10.1182/blood-2007-03-080689.
  19. Khoury J, Cortes JE, Kantarjian H, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119(15):3403–12. doi: 10.1182/blood-2011-11-390120.
  20. Абдулкадыров К.М., Абдуллаев А.О., Авдеева Л.Б. и др. Федеральные клинические рекомендации по диагностике и терапии хронического миелолейкоза. Вестник гематологии. 2013;9(3):4–41.
    [Abdulkadyrov KM, Abdullaev AO, Avdeeva LB, et al. Federal clinical recommendations for the management of chronic myeloid leukemia. Vestnik gematologii. 2013;9(3):4–41. (In Russ)]
  21. Виноградова О.Ю., Асеева Е.А., Воронцова А.В. и др. Влияние различных хромосомных аномалий в Ph-позитивных клетках костного мозга на течение хронического миелолейкоза при терапии ингибиторами тирозинкиназ. Онкогематология. 2012;4:24–34.
    [Vinogradova OYu, Aseeva EA, Vorontsova AV, et al. Influence of different chromosomal abnormalities in Ph-positive bone marrow cells on the chronic myeloid leukemia course during tyrosine kinase inhibitors therapy. Onkogematologiya. 2012;4:24–34. (In Russ)]
  22. Мартынкевич И.С., Мартыненко Л.С., Иванова М.П. и др. Дополнительные хромосомные аберрации у пациентов с хроническим миелолейкозом. Гематология и трансфузиология. 2007;52(2):28–35.
    [Martynkevich IS, Martynenko LS, Ivanova MP, et al. Additional chromosome aberrations in patients with chronic myeloid leukemia. Gematologiya i transfusiologiya. 2007;52(2):28–35. (In Russ)]
  23. Cortes J, Saglio G, Kantarjian H, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naıve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333–41. doi: 10.1200/JCO.2015.64.8899.
  24. Hughes TP, Coutre PD, Jootar S, et al. ENESTnd 5-year follow-up: continued benefit of front line nilotinib (NIL)compared with imatinib (IM) in patients (PTS) with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica. 2014;99(Suppl 1):236–7.
  25. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54. doi: 10.1038/leu.2016.5.
  26. Mahon F-X. Discontinuation of tyrosine kinase therapy in CML. Ann Hematol. 2015;94(Suppl 2):187. doi: 10.1007/s00277-015-2320-4.
  27. Туркина А.Г., Челышева Е.Ю. Стратегия терапии хронического миелолейкоза: возможности и перспективы. Терапевтический архив. 2013;85(7):4–9.
    Turkina AG, Chelysheva EYu. Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects. Terapevticheskii arkhiv. 2013;85(7):4–9. (In Russ)]
  28. Челышева Е.Ю., Туркина А.Г., Шуваев В.А. и др. Результаты наблюдения без терапии ингибиторами тирозинкиназ у больных хроническим миелолейкозом с глубоким молекулярным ответом. Гематология и трансфузиология. 2016;61(1 Suppl 1):80.
    [Chelysheva EYu, Turkina AG, Shuvaev VA, et al. Results of monitoring patients with chronic myeloid leukemia with deep molecular response not receiving tyrosine kinase inhibitors. Gematologiya i transfusiologiya. 2016;61(1 Suppl 1):80. (In Russ)]
  29. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. doi: 10.1182/blood-2013-05-501569.
  30. Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii72–7. doi: 10.1093/annonc/mds228.
  31. Chronic Myeloid Leukemia. NCCN Guidelines. Version I.2017. [Internet] Available from: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf (accessed 12.01.2017).
  32. Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009). [Internet] Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009 (accessed 12.01.2017).
  33. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования. М.: Литтерра, 2016. 298 с.
    [Abdulkadyrov KM, Shuvaev VA, Martynkevich IS. Mieloproliferativnye novoobrazovaniya. (Myleproliferative neoplasms.) Moscow: Litterra; 2016. 298 p. (In Russ)]
  34. Лазарева О.В., Туркина А.Г., Челышева Е.Ю. и др. Клинико-гематологическая характеристика больных при диагностике хронического миелолейкоза: Анализ российских данных в рамках международного популяционного исследования (Population Based Study). Гематология и трансфузиология. 2016;61(1 Suppl 1):136–7.
    [Lazareva OV, Turkina AG, Chelysheva EYu, et al. Clinical and hematological characteristics of patients in diagnosis of chronic myeloid leukeima: analysis of Russian data of Population Based Study. Gematologiya i transfuziologiya. 2016;61(1 Suppl 1):136–7. (In Russ)]
  35. Абдулкадыров К.М. Клиническая гематология: справочник. Санкт-Петербург: Питер Принт, 2006. 748 с.
    [Abdulkadyrov KM. Klinicheskaya gematologiya: spravochnik. (Clinical oncohematology: a reference book.) Saint Petersburg: Piter Print Publ.; 2006. 748 p. (In Russ)]
  36. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood. 1984;63(4):789–99.
  37. Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127(22):2742–50. doi. 10.1182/blood-2016-01-690230.
  38. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood. 2011;118(3):686–92. doi: 10.1182/blood-2010-12-319038.
  39. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232–238. doi: 10.1200/jco.2011.38.6565.
  40. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096–102. doi: 10.1038/leu.2012.85.
  41. Фоминых М.С., Абдулкадыров К.М., Туркина А.Г. и др. Персонализация терапии хронического миелолейкоза — прогностическое значение индивидуальной динамики уровня BCR-ABL. Гематология и трансфузиология. 2016;61(1):4–10. doi: 10.18821/0234-5730-2016-61-1-4-10.
    [Fominykh MS, Abdulkadyrov KM, Turkina AG, et al. Personalization of chronic myelogenous leukemia treatment — prognostic value of the individual rate of BCR-ABL level decline. Gematologiya i transfuziologiya. 2016;61(1):4–10. doi: 10.18821/0234-5730-2016-61-1-4-10. (In Russ)]
  42. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res. 2003;9(6):2092–7.
  43. Marin D, Goldman JM, Olavarria E. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003;102(7):2702–3. doi: 10.1182/blood-2003-06-2042.
  44. Nicolini FE, Turkina AG, Shen Z-X, et al. Expanding Nilotinib Access in Clinical Trials (ENACT). Cancer. 2012;118(1):118–26. doi: 10.1002/cncr.26249.
  45. Giles FJ, Rosti G, Beris P, et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol. 2010;3(6):665–73. doi: 10.1586/ehm.10.61.
  46. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353–60. doi: 10.1182/blood-2013-06-510396.
  47. Radich JP, Martinelli G, Hochhaus A, et al. Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations. Blood. 2015;114(22):1130.
  48. Hughes TP, Munhoz EC, Elhaddad A, et al. Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis. Blood. 2014;124(21):4542.
  49. Tokarski JS, Newitt JA, Chang CYJ, et al. The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants. Cancer Res. 2006;66(11):5790–7. doi: 10.1158/0008-5472.can-05-4187.
  50. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia. Blood. 2008;112(4):1005–12. doi: 10.1182/blood-2008-02-140665.
  51. Keller G, Schafhausen P, Brummendorf TH. Bosutinib: A dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2009;2(5):489–97. doi: 10.1586/ehm.09.42.
  52. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2011;119(5):1123–9. doi: 10.1182/blood-2011-08-376087.
  53. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303–9. doi: 10.1182/blood-2006-09-047266.
  54. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;110(7):2309–15. doi: 10.1182/blood-2007-02-073528.
  55. Cortes J, Rousselot P, Kim D, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207–13. doi: 10.1182/blood-2006-09-046888.
  56. Brummendorf TH, Cortes JE, Kantarjian H, et al. Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). J Clin Oncol. 2011;29(15 Suppl):6535. doi: 10.1200/jco.2011.29.15_suppl.6535.
  57. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–71. doi: 10.1038/leu.2016.104.
  58. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610. doi: 10.1002/ajh.22051.
  59. Гусарова Г.А., Туркина А.Г., Воронцова А.В. и др. Отдаленные результаты терапии дазатинибом и анализ особенностей течения плеврального выпота у больных в поздней хронической фазе хронического миелолейкоза после неудачи лечения иматинибом. Сибирский научный медицинский журнал. 2014;34(6):27–36.
    [Gusarova GA, Turkina AG, Vorontsova AV, et al. Long-term results of therapy by dasatinib and features analysis of the pleural effusion course in patients at late chronic phase of chronic myeloid leukemia after imatinib treatment failure. Sibirskii nauchnyi meditsinskii zhurnal. 2014;34(6):27–36. (In Russ)]
  60. Krauth M-T, Herndlhofer S, Schmook M-T, et al. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011;96(1):163–6. doi: 10.3324/haematol.2010.030494.
  61. Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. J Clin Oncol. 2007;25(25):3908–14. doi: 10.1200/jco.2007.12.0329.
  62. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2):261–3. doi: 10.1182/blood-2008-09-180604.
  63. Справочник лекарственных средств VIDAL. Описание лекарственного препарата Босулиф (Bosulif) [электронный документ]. Доступно по: https://www.vidal.ru/drugs/bosulif__43441. Ссылка активна на 12.01.2017.
    [Vidal Drug Reference to Bosulif [Internet]. Available from: https://www.vidal.ru/drugs/bosulif__43441 (accessed 12.01.2017) (In Russ)]
  64. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374–9. doi: 10.1158/1078-0432.ccr-06-1516.
  65. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Res. 2005;65(11):4500–5. doi: 10.1158/0008-5472.can-05-0259.
  66. Redaelli S, Piazza RR, Magistroni V, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2008;27(3):468–9. doi: 10.1200/jco.2008.19.8853.
  67. US Food and Drug Administration. FDA approves Iclusig to treat two rare types of leukemia. [Internet] Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm (accessed 12.01.2017).
  68. Hochhaus A, Shah N, Cortes JE, et al. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. J Clin Oncol. 2012;30: Abstract 6504.
  69. Kantarjian HM, Kim D-W, Issaragrisil S, et al. ENESTnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic phase (CML-CP). Blood. 2012;120:1676.
  70. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010;3(1):47. doi: 10.1186/1756-8722-3-47.
  71. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol. 2008;26(15 Suppl):7009. doi: 10.1200/jco.2008.26.15_suppl.7009.
  72. Горбунова А.В., Гиндина Т.Л., Морозова Е.В. и др. Влияние молекулярно-генетических и цитогенетических факторов на эффективность аллогенной трансплантации костного мозга у больных хроническим миелолейкозом. Клиническая онкогематология. 2013;6(4):445–50.
    [Gorbunova AV, Gindina TL, Morozova EV, et al. Impact of molecular genetic and cytogenetic characteristics on outcomes of allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia. Klinicheskaya onkogematologiya. 2013;6(4):445–50. (In Russ)]
  73. Silva L, Cortes J, Jabbour E, et al. Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. Blood. 2008;112(11):2154.
  74. Weisser M, Schleuning M, Haferlach C, et al. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma. 2007;48(2):295–301. doi: 10.1080/10428190601078464.
  75. Nicolini F, Modolo L, Raus N, et al. Allogeneic stem cell transplantation for blast crisis CML in TKI era, analysis of pre-transplant variables on transplant outcome. Blood. 2010;116:2266.
  76. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352(9134):1087–92. doi: 10.1016/s0140-6736(98)03030-x.
  77. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). [Internet] Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5х7.pdf. (accessed 12.01.2017).
  78. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Дазатиниб: 10 лет применения в мировой клинической практике. Онкогематология. 2016;11(1):24–33.
    [Abdulkadyrov KM, Shuvaev VA, Martynkevich IS. Dasatinib: ten years of clinical practice worldwide. Onkogematologiya. 2016;11(1):24–33. (In Russ)]
  79. Larson RA, le Coutre PD, Reiffers J, et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. J Clin Oncol. 2010;28(15 Suppl):6501. doi: 10.1200/jco.2010.28.15_suppl.6501/
  80. Диагностика и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр [электронный документ]. Доступно по: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf. Ссылка активна на 12.01.2017.
    [Diagnosis and treatment of lipid metabolism disorders in atherosclerosis prevention and treatment. Russian clinical guidelines. Fifth review [Internet]. Available from: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf. (accessed 12.01.2017) (In Russ)]
  81. Cortes JE, Jimenez CA, Mauro MJ, et al. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clin Lymph Myel Leuk. 2017;17(2):78–82. doi: 10.1016/j.clml.2016.09.012.
  82. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43(12):967–8. doi: 10.1038/bmt.2008.415.
  83. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37. doi: 10.1161/CIRCULATIONAHA.111.079921.
  84. Shah NP, Wallis N, Farber HW Clinical feature of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90(11):1060–4. doi: 10.1002/ajh.24174.
  85. Лазарева О.В., Костина И.Э., Туркина А.Г. Лекарственно-индуцированный пневмонит: редкое осложнение терапии иматиниба мезилатом у больных хроническим миелолейкозом. Клиническая онкогематология. 2010;1(3):47–52.
    [Lazareva OV, Kostina IE, Turkina AG. Drug-induced pneumonitis: rare complication of imatinib mesylate therapy in patients with chronic myeloid leukemia. Klinicheskaya onkogematologiya. 2010;1(3):47–52. (In Russ)]
  86. Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs. 2012;23(7):754–7. doi: 10.1097/CAD.0b013e328352a8fe.
  87. Cortes JE, Abruzzese E, Chelysheva E. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111–5. doi: 10.1002/ajh.24186.
  88. Репродуктивное здоровье женщин с онкогематологическими заболеваниями. Под ред. Г.Т. Сухих, М.И. Давыдова, В.Г. Савченко. М.: ООО «Компания Боргес», 2012. 310 c.
    [Sukhikh GT, Davydov MI, Savchenko VG, eds. Reproduktivnoe zdorov’e zhenshchin s onkogematologicheskimi zabolevaniyami. (Reproductive health of women with oncohematological diseases.) Moscow: Borges Company, LLC, Publ.; 2012. 310 p. (In Russ)]
  89. Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27(4):241–3. doi: 10.1038/sj.jp.7211665.
  90. Breccia M, Cannella L, Montefusco E, et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases. Leuk Res. 2008;32(3):519–20. doi: 10.1016/j.leukres.2007.07.022.
  91. Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009). [Internet] Available from: http://www.cebm.net/index.aspx?o=1025 (accessed 24.02 2017).

Russian clinical recommendations on diagnosis and management of diffuse B-large cell lymphoma (version 2012).

CLINICAL GUIDELINES

Tumyan G.S., Osmanov Ye.A., Kravchenko S.K., Mikhaylova N.B., Pospelova T.I., Konstantinova T.S., Baykov V.V., Kovrigina A.M., Krivolapov YU.A., Kokosadze N.V., Tupitsyn N.N., Sotnikov V.M., Trofimova O.P., Stefanov D.N., Pfreundschuh M., Poddubnaya I.V.

Read in PDF (RUS)pdficon

References

  1. Harris N.L., Jaffe E.S., Diebold J. et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999; 17(12): 3835–49.
  2. Swerdlow S.H., Campo E., Harris N.L. et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008.
  3. Hans C.P., Weisenburger D.D., Greiner T.C. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103(1): 275–82.
  4. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl. J. Med. 1993; 329(14): 987–94.
  5. Kridel R., Dietrich P.Y. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011; 12: 1258–66.
  6. Pfreundschuh M., Trumper L., Osterborg A. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379–91.
  7. Miller T.P., Dahlberg S., Cassady J.R. et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med. 1998; 339(1): 21–6.
  8. Shenkier T.N., Voss N., Fairey R. et al. Brief chemotherapy and involvedregion irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J. Clin. Oncol. 2002; 20(1): 197–204.
  9. Horning S.J., Weller E., Kim K. et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J. Clin. Oncol. 2004; 22(15): 3032–8.
  10. Bonnet C., Fillet G., Mounier N. et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 2007; 25(7): 787–92.
  11. Phan J., Mazloom A., Medeiros L.J. et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J. Clin. Oncol. 2010; 28(27): 4170–6.
  12. Румянцев А.Г., Птушкин В.В., Семочкин С.В. Пути улучшения результатов лечения злокачественных опухолей у подростков и молодых взрослых. Онкогематология 2011; 1: 20–30. Rumyantsev A.G., Ptushkin V.V., Semochkin S.V. Puti uluchsheniya rezultatov lecheniya zlokachestvennykh opukholey u podrostkov i molodykh vzroslykh [Approaches to improvement of treatment outcomes in adolescents and young adults with malignancies. In: Oncohematology]. Onkogematologiya 2011; 1: 20–30.
  13. Reiter A., Schrappe M., Tiemann M. et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-M nster Group Trial NHL-BFM 90. Blood. 1999; 94(10): 3294–306.
  14. Бобкова М.М., Семочкин С.В., Иванова В.Л. и др. Эффективность применения интенсивной полихимиотерапии в лечении молодых больных с диффузной В-крупноклеточной лимфомой из клеток герминального центра. Онкогематология 2009; 4: 4–11. [Bobkova M.M., Semochkin S.V., Ivanova V.L. i dr. Effektivnost primeneniya intensivnoy polikhimioterapii v lechenii molodykh bolnykh s diffuznoy V-krupnokletochnoy limfomoy iz kletok germinalnogo tsentra (Efficacy of intensive polychemotherapy in young patients with diffuse large B-cell lymphoma from germinal center. In: Oncohematology). Onkogematologiya 2009; 4: 4–11.]
  15. Wilson W.H., Dunleavy K., Pittaluga S. et al. Phase II study of doseadjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J. Clin. Oncol. 2008; 26(16): 2717–24.
  16. Coiffier B., Lepage E., Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346: 235–42.
  17. Peyrade F., Jardin F., Thieblemont C. et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011; 12: 460–8.
  18. Chao N.J., Rosenberg S.A., Horning S.J. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin’s lymphoma. Blood 1990; 76(7): 1293–8.
  19. Moccia A.A., Schaff K., Hoskins P. et al. R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 408.
  20. Philip T., Guglielmi C., Hagenbeek A. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N. Engl. J. Med. 1995; 333(23): 1540–5.
  21. Velasquez W.S., Cabanillas F., Salvador P. et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71(1): 117–22.
  22. Velasquez W.S., McLaughlin P., Tucker S. et al. ESHAP — an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year followup study. J. Clin. Oncol. 1994; 12(6): 1169–76.
  23. Crump M., Baetz T., Couban S. et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell nonHodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101(8): 1835–42.
  24. Kuruvilla J., Nagy T., Pintilie M. et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106(2): 353–60.
  25. Zelenetz A.D., Hamlin P., Kewalramani T. et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann. Oncol. 2003; 14(Suppl. 1): i5–10.
  26. Coiffier B., Haioun C., Ketterer N. et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92(6): 1927–32.
  27. Мангасарова Я.К., Магомедова А.У., Кравченко С.К. и др. Диффузная В-крупноклеточная лимфома с первичным вовлечением лимфоузлов сре- достения: диагностика и лечение. Тер. арх. 2010; 7: 61–5. [Mangasarova Ya.K., Magomedova A.U., Kravchenko S.K. i dr. Diffuznaya V-krupnokletochnaya limfoma s pervichnym vovlecheniyem limfouzlov sredosteniya: diagnostika i lecheniye (Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment. In: Ther. archive). Ter. arkh. 2010; 7: 61–5.]
  28. Кичигина М.Ю., Тумян Г.С., Ковригина А.М. и др. Первичная медиа- стинальная (тимическая) В-крупноклеточная лимфома: обзор литературы и собственные данные. Тер. арх. 2011; 83(7): 38–46. [Kichigina M.Yu., Tumyan G.S., Kovrigina A.M. i dr. Pervichnaya mediastinalnaya (timicheskaya) V-krupnokletochnaya limfoma: obzor literatury i sobstvennye dannye (Primary mediastinal (thymic) large B-cell lymphoma: literature review and our own findings. In: Ther. archive). Ter. arkh. 2011; 83(7): 38–46.]
  29. Savage K.J., Al-Rajhi N., Voss N. et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann. Oncol. 2006; 17(1): 123–30.
  30. Zinzani P.L., Stefoni V., Finolezzi E. et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin. Lymph. Myel. 2009; 9(5): 381–5.
  31. Rieger M., Osterborg A., Pettengell R. et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann. Oncol. 2011; 22(3): 664–70.
  32. Vassilakopoulos T.P., Angelopoulou M.K., Galani Z. et al. RituximabCHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL). Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 2745.
  33. Dunleavy K., Pittaluga S., Janik J. et al. Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients. Blood (ASH Annual Meeting Abstracts). 2006; 108: Abstract 209.
  34. Тумян Г.С., Сорокин Е.Н., Ковригина А.М. и др. Диффузная В-крупноклеточная лимфома с первичной локализацией в яичке. Клини- ческая онкогематология. Фунд. исслед. и клин. практ. 2008; 1(3): 206–10. [Tumyan G.S., Sorokin Ye.N., Kovrigina A.M. i dr. Diffuznaya V-krupnokletochnaya limfoma s pervichnoy lokalizatsiyey v yaichke (Diffuse large B-cell lymphoma with primary testicular involvement. In: Clinical hematology. Fund. stud. & clin. pract.). Klinicheskaya onkogematologiya. Fund. issled. i klin. prakt. 2008; 1(3): 206–10.]
  35. Сотникова О.П., Сорокин Е.Н., Поддубная И.В. Первичные неход- жкинские лимфомы яичка. Онкоурология 2012; 1: 88–94. [Sotnikova O.P., Sorokin Ye.N., Poddubnaya I.V. Pervichnye nekhodzhkinskiye limfomy yaichka (Primary non-Hodgkin’s testicular lymphomas. In: Oncourology). Onkourologiya 2012; 1: 88–94.]
  36. Gundrum J.D., Mathiason M.A., Moore D.B., Go R.S. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J. Clin. Oncol. 2009; 27(31): 5227.
  37. Mazloom A., Fowler N., Medeiros L.J., Iyengar P. et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M.D. Anderson Cancer Center experience. Leuk. Lymphoma 2010; 51(7): 1217–24.
  38. Vitolo U., Ferreri A.J., Zucca E. Primary testicular lymphoma. Crit. Rev. Oncol. Hematol. 2008; 65(2): 183–9.
  39. Hasselblom S., Ridell B., Wedel H. et al. Testicular lymphoma e a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol. 2004; 43(8): 758–65.
  40. Пересторонина Т.Н., Кравченко С.К., Губкин А.В. и др. Первичная диффузная В-крупноклеточная лимфосаркома яичка с вовлечением центральной нервной системы. Гематол. и трансфузиол. 2009; 54(3): 25–7. [Perestoronina T.N., Kravchenko S.K., Gubkin A.V. i dr. Pervichnaya diffuznaya V-krupnokletochnaya limfosarkoma yaichka s vovlecheniyem tsentralnoy nervnoy sistemy (Primary diffuse large B-cell testicular lymphosarcoma with involvement of central nervous system. In: Hematol. & transfusiol.). Gematol. i transfuziol. 2009; 54(3): 25–7.]
  41. Vitolo U., Chiappella A., Ferreri A.J. et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J. Clin. Oncol. 2011; 29(20): 2766–72.
  42. Ahmad S.S., Idris S.F., Follows G.A., Williams M.V. Primary Testicular Lymphoma. Clin. Oncol. (R. Coll. Radiol). 2012; 24(5): 358–65.